<DOC>
	<DOCNO>NCT00677924</DOCNO>
	<brief_summary>The purpose trial determine safety efficacy Zalutumumab alone combination Irinotecan treatment patient Colorectal Cancer</brief_summary>
	<brief_title>Zalutumumab With Without Irinotecan Chemotherapy Cetuximab-Refractory Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Males Females age â‰¥ 18 year 2 . Confirmed diagnosis CRC 3 . Documented disease progression 4 . Failure and/or intolerance standard chemotherapy 1 . Prior treatment antiEGFR antibody cetuximab 2 . Expected survival &lt; 3 month 3 . Clinical significant cardiac disease and/or uncontrolled medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>Colorectal Tumors</keyword>
	<keyword>Colorectal Carcinoma</keyword>
</DOC>